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1. Introduction 
Renal transplantation is considered to be the treatment of choice for patients with ESRD. 
The incidence of ESRD is increasing, as a result of the increase in diabetes as well as other 
CKD causes. However the rise in ESRD is not matched by a rise in available kidneys for 
transplantation. As cadaveric kidneys have failed to meet the growing need for organs, 
attention has turned to organs from living donors [1].  
2. History of living kidney donation and justification 
2.1. First identical twin transplant 
The first successful kidney transplant program was at The Peter Bent Brigham hospital in 
Boston. There, in December 1954, Dr. Joseph Murray performed the first successful kidney 
transplant between identical twins. The recipient’s renal disease was presumably secondary 
to chronic glomerulonephritis. The opportunity of transplantation was suggested since the 
patient had a healthy twin brother. Cross skin grafting was performed between the 2 
brothers and skin grafts survived for weeks establishing “genetic identity”. Thirty days after 
the skin grafting, the transplant was performed; Dr. Hartwell Harrison removed the donor 
kidney, which was implanted in the recipient by Dr. Joseph Murray. The team performed 
seven more such transplants during the next four years. The patient died after eight years 
due to development of recurrent glomerulonephritis in the transplanted kidney [2-4]. 
2.2. Long-term survival of living kidney donor allografts 
For recipients of a first deceased kidney in the United States, current 1-year patient and graft 
survival probabilities are about 95% and 88%, respectively. For recipients of a first living 
donor kidney, current 1-year patient and graft survival probabilities are 98% and 94%, 
respectively [5]. Improved immunosuppressive medications have decreased early acute 
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rejection. However, despite the improved short term survival, graft survival half-lives have 
increased only very little, but are almost two-fold higher in recipients of living donors than 
those in patients receiving a transplant from a deceased donor (ten years for deceased 
donors versus 20 years for living donors).[6] The slow improvement in long term survival is 
related in part to chronic allograft nephropathy (CAN) as well as the nephrotoxic effect of 
calcineurin inhibitors. Stronger immunosuppressive regimens lead to increased incidence of 
malignancies and infections that may alter renal function. Immunosuppressive medications 
can also have unfavorable effects on blood pressure, glycemic control and lipid levels that 
may also lead to worsening renal function.  
According to the UNOS renal transplant registry, estimated cadaveric graft half-lives were 7.9 
years for the 1988-1989 (2- year) cohort, 9.2 years for the 1994-1995 cohort, and 11.6 years for 
the 1998-1999 cohort, despite the concurrent greater use of organs from older and less optimal 
deceased donors. Estimated living donor graft half-lives were 12.5 years for the 1988-1989 
cohort, 15.8 years for the 1994-1995 cohort, and 19.3 years for the 1998-1999 cohort [7]. 
Graft survival in living transplants may be favorably affected by the relatively low delayed 
graft function rates (4 % vs. 24 % in cadaveric transplants) [8].  
2.3. Insufficient supply of cadaveric allografts, Limiting waitlist time 
As the incidence of ESRD is rising, kidney transplantation has failed to keep pace. Despite 
all the efforts to increase deceased kidney donation, there is still a shortage of deceased 
kidneys leading to increasing times on the waiting list. This implies increased workload for 
the transplantation centers, to ensure that patients on the waitlist remain fit enough to be 
able to receive a transplant [5]. Efforts have been made to use deceased organs that might 
have formerly not been used. Examples of this are the increased use of Expanded Criteria 
Donor (ECD) kidneys as well as use of donation after cardiac death (DCD) organs [6]. 
This organ shortage has also created a number of ethical and social dilemmas that vary 
across different countries of the world. The prevalence of kidney transplant from living 
donors varies widely around the globe. Factors such as the availability of deceased donors, 
the role of the government, the attitude of local physicians towards the risks of living 
donation, the level of awareness and education about ESRD and transplantation among the 
general population all affect the rates of donation. The proportion of kidney transplant from 
living kidney donors is less than 15 % in most European countries, except for the United 
Kingdom, where it has reached 47% in the last few years [9]. This proportion is only 3.3% in 
Finland, 8% in France, 12% in Belgium, compared to 49.5% in the USA [10]. In Spain, 
efficient identification of deceased renal donors has kept the waiting time short and living 
donors account for less than 5% of all kidney transplants. In Japan, social and cultural 
barriers have limited deceased donor transplantation and living donors account for 80% of 
kidney transplants [11]. In other countries like Egypt and Pakistan, living donor kidney 
transplant is the sole method of transplant available.  
Transplantation increases the survival of patients with renal failure when compared to 
dialysis. One study of United States Renal Data System (USRDS) data compared outcomes 
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in patients on the transplant waiting list (who were continuing to receive dialysis) versus 
those who had received a kidney transplant. It found that, after 3 to 4 years of follow-up, 
transplantation reduced the risk of death overall by 68 % [1]. Transplantation conferred a 
survival benefit in almost all subgroups. In addition, over the long term, it is more cost-
efficient than dialysis. Thus, transplantation remains the optimal therapy for patients with 
ESRD [5]. 
3. Team approach to donor selection and evaluation 
3.1. Medical 
3.1.1. Amsterdam Forum Guidelines 
In April 2004, renal transplant physicians and surgeons met in Amsterdam, The 
Netherlands, for the International Forum on the Care of the Live Kidney Donor. The 
participants included over 100 experts in transplantation from more than 40 countries [12]. 
The main purpose of this forum was to develop an international consensus on the standards 
of care for the living kidney donor and to emphasize the concern of the transplant 
community for the welfare of the donor. It also formed an alliance with the World Health 
Organization (WHO) to implement these standards of care, in continuation to the Madrid 
WHO conference on organ donation and transplantation that was held in October 2003. The 
forum emphasized the low operative risk of renal transplantation that has a perioperative 
mortality rate of 0.03% [13]. It also stressed the importance of long-term safety of this 
procedure noting the absence of accelerated loss of renal function and lack of appearance of 
hypertension in healthy donors post nephrectomy. The forum elaborated in detail about the 
acceptance criteria of donors with hypertension, obesity, dyslipidemia, low-normal renal 
function, hematuria, proteinuria, stone disease and other factors. 
3.1.2. General medical evaluation and informed consent 
The medical evaluation starts with a general assessment that includes a detailed history and 
physical examination, age appropriate medical screening, and a determination of 
contraindications to kidney donation such as active malignancy, active infection, 
transmissible conditions among other conditions that will be discussed in detail below.  
Elements of the living donor evaluation vary across different transplant centers. Some of the 
major components of the general medical evaluation are outlined in table 1 [14].  
Donor age: 
Almost all transplant centers preclude individuals younger than 18 years old from donating 
and consider the age of 18–21 years as a relative contraindication to donation. Young donors 
with even what seems like mild or borderline risk factors should be evaluated more 
stringently as they have many years ahead of them to potentially develop medical 
conditions that may harm the remaining kidney such as diabetes and hypertension [14]. In 
fact, the OPTN (Organ Procurement and Transplantation Network) data showed that most  
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Blood group, HLA typing, crossmatch 
Urinalysis and urine culture 
24 hour urine collection for protein and creatinine clearance 
CBC, Prothrombin time, Partial thromboplastin time 
Comprehensive metabolic panel (electrolytes, albumin, alkaline phosphatase, 
 transaminases, Calcium, phosphorus, bilirubin) 
Infectious screen: HIV, hepatitis B and C, Epstein-Barr virus, cytomegalovirus, herpes 
 simplex virus, RPR, tuberculosis (PPD, quantiferon) and if indicated, screen for 
 toxoplasma, trypanosoma, malaria, West Nile. 
Human chorionic gonadotropin quantitative pregnancy test in women younger than 55 
 years 
Fasting blood glucose and lipid profile 
Hemoglobin A1c, glucose tolerance test as clinically indicated 
ECG, CXR 
Echocardiography, cardiac stress testing if clinically indicated 
Age appropriate cancer screening:  
 mammogram, pap smear for women 
 PSA for men 
 colonoscopy 
Renal imaging: CT angiogram or Magnetic resonance angiogram 
Table 1. Living donor medical evaluation [14] 
of the donors who were later listed on the transplant list donated between the ages of 18 and 
34 years and developed ESRD more than 15 years after donating [15]. In a 2007 survey of US 
transplant centers, 21% of the centers list the age of 65 as an upper limit to exclude donation, 
while 60% don’t set an upper age limit for donation [16]. Donation from well selected older 
donors (>60 years old) appears to be safe and has good short and long term outcomes. Well 
selected older donors have no difference in perioperative outcomes when compared to 
younger donors [17,18]. 
Informed consent: 
Living donor transplantation creates a conflict between the duty to do no harm and the duty 
to respect the donor’s autonomy [19]. A fundamental part of the donor evaluation is 
informed consent. The elements of the informed consent process include a careful 
assessment of the donor’s capacity to make medical decisions and understand the 
information provided. The donor should be informed in detail about: 
 the different elements of the donor evaluation process 
 the surgical procedure and the recovery period 
 the potential medical or psychosocial risks to the donor 
 the short and long-term follow-up care requirements 
 the quality of life after donation 
 the availability of alternative treatments for the transplant recipient 
 the recipient’s risks, recurrent disease, and chances for survival 
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 national and center-specific outcomes for recipients and living donors  
 the possibility that the donor’s medical evaluation could reveal conditions that the 
transplant program must report to governmental authorities, such as infection with the 
human immunodeficiency virus 
 the possibility that future health problems related to the donation may not be covered 
by the donor’s insurance and the ability to obtain health disability or life insurance may 
be affected 
 the donor’s right to opt out of donation at any time during the donation process. 
(adapted from The living donor advocate: a team approach to educate, evaluate, and manage donors 
across the continuum [20]) 
3.1.3. Hypertension  
Hypertension (HTN) has been considered as a risk factor for chronic kidney disease (CKD). 
Screening for hypertension in a potential donor includes blood pressure (BP) measurement 
on three separate occasions [12]. Other experts advocate the use of ambulatory blood 
pressure monitoring (ABPM) [21].   
Hypertension, defined by JNC7 as Systolic BP > 140 mm and/or Diastolic BP > 90 mm Hg or 
an average daytime blood pressure > 135/85 on ABPM, is a relative contraindication for 
renal transplantation. Most renal transplant centers exclude potential donors with BP 
greater than 140/90 by ABPM from donation. The prospective donor should have a mean 
awake BP less than 135/85 mm Hg and a BP less than 120/75 mm Hg when asleep.  
On the other hand, the association of HTN with CKD has been argued in other studies. The 
RHEDY Study examined 1856 patients with primary HTN, with an average age of 47 years. 
Microalbuminuria and macroalbuminuria were detected, respectively, in 22.7 and 0.7% of 
the entire population. Systolic BP and abdominal obesity were two important determinants 
of microalbuminuria. However, only 5.2% of patients had simultaneously albuminuria and 
a reduced estimated GFR, implying a weak relation to one another [22].  
Renal outcomes of kidney donors who were hypertensive at baseline were found to be 
favorable in some studies. Gil Thiel reported 18 donors who were hypertensive at the time 
of nephrectomy. The renal function, assessed by the creatinine clearance, of the 18 donors 
who were hypertensive at nephrectomy, was no different than the 75 normotensive donors 
[23]. In a report from Stegall from the Mayo clinic, 24 donors had hypertension, as defined 
by awake ABPM>135/85 mm Hg and/or office BP>140/90 mm Hg before donation. 
Hypertensive donors were older (53.4 vs. 41.4 years, P<.0001). The GFR (determined by 
iothalamate clearance) of the 24 hypertensive donors was not statistically different than 150 
normotensive donors prior to nephrectomy or at 1 year postdonation. None of the subjects 
had albuminuria [24]. 
The following consensus guidelines regarding hypertensive donors were adopted at the 
Amsterdam Forum on the Care of the Live Kidney Donor [12]: 
 Patients with a BP > 140/90 mmHg by ABPM are generally not acceptable as donors.  
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 BP should preferably be measured by ABPM, particularly among older donors (≥50 
years and/or those with high office BP readings.  
 Some patients with easily controlled hypertension who meet other defined criteria (e.g., 
>50 years of age, GFR ≥ 80 mL/min/1.73m2, and urinary albumin excretion < 30 mg/day) 
may represent a low-risk group for development of kidney disease after donation and 
may be acceptable as kidney donors.  
 In cases with borderline high BP, and/or abnormalities suggesting cardiomegaly, or left 
ventricular hypertrophy on chest radiograph or electrocardiogram, an echocardiogram 
may be considered to evaluate for cardiac hypertrophy.  
Patients with borderline BP and/or easily controlled hypertension can be considered for 
donation if they meet the following criteria [12]: 
 more than 50 years of age 
 not African American 
 urine albumin excretion<30mg/day 
 no signs of end organ damage 
 GFR>80ml/min/1.73m2  
3.1.4. Nephrolithiasis 
Nephrolithiasis affects 12% of the population and is increasing in prevalence [25]. The 
routine evaluation of kidney donor should include screening for kidney stones. The risk of 
kidney donation in a stone former includes the risk of stone recurrence and development of 
obstructive uropathy as well as urinary tract infections that may lead to worsening kidney 
function. Most stones are calcium containing stones, and carry a 50% recurrence risk at 5-10 
years [26]. Patients with nephrolithiasis should be screened for metabolic abnormalities that 
predispose to stone formation.  
Burgher et al conducted a retrospective evaluation of 300 male patients, 62.8 years old on 
average, who were followed for a mean of 3.26 years for asymptomatic renal calculi. Mean 
stone diameter was 10.8mm. 77% of patients experienced disease progression, with 26% 
requiring surgical intervention. Stone size, blood and urine uric acid level were associated 
with increased risk of growth. Small (<4mm), non uric acid, upper-pole calculi in patients 
with normal metabolic profile had the slowest progression [25]. 
After unilateral nephrectomy for pyelonephritis in patients with stone disease, the overall 
risk for stone recurrence is about 30% over a mean follow up of 5 years. In this study, the 
kidney function remained normal over the 5 year follow up period [27].  
According to the Amsterdam forum,[12] an asymptomatic potential donor with history of a 
single stone may be suitable for kidney donation if: 
 No hypercalcuria, hyperuricemia, metabolic acidosis, hypocitraturia, cystinuria or 
hyperoxaluria 
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 No urinary tract infection 
 Multiple stones or nephrocalcinosis are not evident on computed tomography (CT) scan 
Asymptomatic potential donor with current single stone may be suitable if [12]: 
 The donor meets the criteria shown previously for single stone formers, and 
 Current stone is <1.5 cm in size or potentially removable during transplant 
 No evidence of nephrocalcinosis on imaging 
Stone formers who should not donate are those with [12]: 
 Nephrocalcinosis on X ray 
 Multiple stone in one kidney or bilateral stone disease; and 
 Stone types that have high recurrence rates and are difficult to prevent, such as: 
 Cystine stones that have a high rate of recurrence 
 Struvite stones or infection stones, which would be difficult to eradicate in an 
immunosuppressed host 
 Stones associated with inherited or other systemic disorders, such as primary or 
enteric hyperoxaluria, distal renal tubular acidosis, sarcoid and inflammatory 
bowel disease  
 Recurrence while on appropriate treatment 
Spiral CT is the imaging technique of choice to detect stones or nephrocalcinosis. Age is an 
important clinical parameter that predicts recurrence since a stone detected in a person older 
than 50 years is unlikely to recur, whereas stone recurrence is higher in subjects aged 25-35 
years [28]. 
3.1.5. Obesity 
Obesity is defined by a BMI greater than 30kg/m2. Obesity has been regarded as a risk factor 
for surgical complications, diabetes, glomerular disease (focal segmental glomerulosclerosis) 
with proteinuria, hypertension and ESRD in prospective living donors [29]. The relative risk 
for developing ESRD is threefold for a BMI between 30 and 35 kg/m2 and nearly fivefold for 
a BMI of 35–40 kg/m2 [30].  
Obesity was shown to have a positive correlation with the development of proteinuria and 
renal insufficiency in patients who had previously undergone nephrectomy and who had 
normal renal function and no proteinuria at the time of the nephrectomy. Praga et al 
conducted a cross-sectional study in 73 patients who had undergone unilateral nephrectomy 
with normal kidney function at the time of nephrectomy. Indications for nephrectomy were 
stones, renal mass, pyelonephritis, hydronephrosis or tuberculosis. The group of patients 
who developed proteinuria and renal insufficiency at follow up had a mean BMI of 31 at the 
time of nephrectomy in comparison with a BMI of 24 in the group who did not have any 
proteinuria or renal insufficiency. The time elapsed between nephrectomy and onset of 
proteinuria was 10.1 +/- 6.1 years. The time elapsed between proteinuria appearance and the 
onset of renal insufficiency was 4.1 +/- 4.3 years [31].  
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On the other hand, a retrospective analysis of 553 kidneys donors showed that obese 
(BMI>35) vs. non obese (BMI<25) donors had a similar peri-operative complications except 
for more wound infections (9% vs. 94%) and longer operative time (mean increase 19 
minutes) in the obese group. Both groups had similar GFR at 1 year and no blood pressure 
elevation or proteinuria at 1 year follow up [32].  
About 50% of transplant centers in the USA exclude potential donors with BMI more than 
35, and 10% exclude donors with BMI above 30kg/m2 [26]. The Amsterdam Forum on the 
Care of the Live Kidney Donor [12] suggested that patients with a BMI > 35 kg/m2 should be 
discouraged from donating, especially when other comorbid conditions are present and 
encouraged to adopt healthy lifestyle and to lose weight. 
3.1.6. Diabetes 
Diabetes Mellitus is defined as having fasting plasma glucose level of at least 126mg/dl or a 
plasma glucose level of at least 200mg/dl 2 hours after a 75 grams glucose challenge, 
confirmed by a repeat testing on a different day (see table 2).  
 
 Prediabetes Diabetes 
Fasting plasma glucose 
(mg/dl) 
100-125 
(impaired fasting glucose: IFG) 
≥ 126 
2 hr plasma glucose after 
75g glucose load (mg/dl) 
140-199 
(impaired glucose tolerance: IGT)
≥200 
Hemoglobin A1c 5.7-6.4% ≥6.5% 
Table 2. Diagnostic criteria for Diabetes and Prediabetes 
All potential living donors should have a fasting plasma glucose testing. Those with fasting 
plasma glucose between 100 and 125 mg/dl and patients with risk factors for diabetes 
(BMI>30, parent or first degree relative with diabetes, history of gestational diabetes, 
delivery of large birth weight baby (>9lbs), BP>140/90, dyslipidemia, vascular disease, 
history of alcohol abuse, polycystic ovary syndrome, acanthosis nigricans), should have an 
oral glucose tolerance test (OGTT). Donors younger than 40 years old with a second-degree 
relative with type 2 diabetes should also undergo an OGTT [26]. 
Single kidney diabetic patients have higher proportion of albuminuria and lower GFR than 
single kidney non diabetic patients and diabetic patients with 2 kidneys [33]. Most 
transplantation centers regard established diabetes mellitus as a contraindication to living 
donation. According to International Amsterdam forum on living donor care, individuals 
with a history of diabetes or fasting blood glucose of ≥126 mg/dl on at least two occasions 
(or 2-h glucose with OGTT ≥ 200mg/dl) should be precluded from donating [12]. 
Prediabetes is viewed as a relative contraindication to living donation. Prospective donors 
with prediabetes (IFG, IGT) should be assessed on an individual basis. A study by Okamoto 
of 44 donors with impaired glucose tolerance concluded that these patients had equal 
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survival compared to a non-diabetic cohort at 5, 10, and 20 years. None of these prediabetic 
donors had chronic kidney disease or required diabetic medications at mean follow-up 
point of 7 years [34]. Individuals with prediabetes should be counseled about lifestyle 
modifications, healthy diet, exercise, and smoking cessation. They should be counseled 
about the risk of progression to overt diabetes. Experts recommend against donation in 
patients who have impaired glucose tolerance and additional risk factors, as listed above. 
Patients with impaired fasting glucose in the high range have a high risk of progression to 
diabetes and are discouraged from donation.  
3.1.7. Inheritable diseases 
When evaluating related living donors, special attention should be given to evaluate for 
potential inherited renal diseases. An extensive family history of renal disease 
manifestations, as well as extrarenal manifestations, namely hearing and ocular 
abnormalities and biopsy documentation of recipient’s renal disease provide critical 
information in the decision-making process of kidney donation [35].  
APKD 
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary 
renal disease, occurring in 1 in 400–1,000 live births, and accounting for more than 5% of 
cases of ESRD in Europe and North America. 85 % of the cases are secondary to a mutation 
in PKD1 gene on chromosome 16, which encodes polycystin1 and progress to ESRD at a 
mean age of 54 years. The remaining 15% of the cases are caused by a mutation in PKD2 
gene, located on chromosome 4, that encodes for polycystin 2 and manifest with ESRD at the 
age of 74 [36]. 
The diagnosis of ADPKD is made based on age-specific criteria. In families of unknown 
genotype, the presence of 3 or more (unilateral or bilateral) renal cysts is sufficient for 
establishing the diagnosis in individuals aged 15 to 39 years, two or more cysts in each 
kidney is sufficient for individuals aged 40 to 59 years, and four or more cysts in each 
kidney is required for individuals ≥60 years. Conversely, fewer than two renal cysts in at-
risk individuals aged ≥40 years are sufficient to exclude the disease [37].  
In at risk individuals aged more than 30 years, absence of cysts by ultrasound excludes 
diagnosis of ADPKD in 98% of cases. In at risk individuals less than 30 years, a negative 
ultrasound does not rule out the disease; more sensitive imaging is needed such as CT 
Scanning and T2 weighted MRI which are more sensitive in detecting small cysts (<2-
3mm). In potential donors aged <30 years, a negative renal ultrasound scan does not 
exclude type 2 ADPKD; however, a negative renal ultrasound scan and a negative CT 
scan may be adequate to exclude type 1 ADPKD in such donors [35]. When results of 
imaging are equivocal, genetic testing is available. This includes linkage analysis and gene 
sequencing. Linkage analysis requires multiple affected and unaffected family members. 
However, in clinical practice, it is difficult to elucidate an extensive family history of 
ADPKD. In that case, direct PKD gene sequence analysis would be required and is the 
most commonly used genetic testing. Because of the high prevalence of polymorphisms, 
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the diagnosis is established unequivocally by gene sequencing in only about 40–60% of all 
cases [38].  
The failure to confirm or exclude the diagnosis of ADPKD has broad implications for both 
the donor and recipient, especially when the prospective donor is a young family member, 
in whom ultrasonography is less likely to be helpful. Huang et al [39] attempted to provide 
a diagnostic strategy that is based on genetic testing of live kidney donors at 50% risk for 
ADPKD in whom renal imaging studies are inconclusive. First, if genetic linkage analysis is 
not feasible, then the prospective recipient undergoes PKD gene sequencing. If a PKD gene 
mutation is identified then directed genetic testing of the donor is done. A donor is 
ineligible if the genetic test is positive. If the mutation is not found in the donor, then the 
diagnosis of ADPKD is excluded and transplantation can proceed. If the recipient’s genetic 
test is indeterminate, then genotyping of the donor is not performed and donation is 
deferred. This strategy is likely to increase the number of renal transplants from living 
related donors who would otherwise have been excluded by their indeterminate renal 
imaging. It can also uncover undiagnosed ADPKD. On the other hand, the diagnostic 
sensitivity of direct sequencing is relatively low, especially for the PKD1 gene, because it is 
highly polymorphic. The test is expensive and adds to the cost of pretransplant evaluation. 
In summary, living donation is contraindicated in potential donors aged <30 years old for 
whom imaging techniques do not show cysts but for whom genetic tests show positive 
results for mutated PKD genes, although no data exist on the risk of ESRD in such 
individuals [35]. It is considered safe to proceed with kidney donation if imaging studies 
and genetic studies exclude ADPKD. 
Alport’s syndrome 
In approximately 85% of patients, Alport syndrome is inherited as an X linked disease and is 
caused by mutations in the COL4A5 gene, which encodes the α5 chain of type IV collagen. 
De novo mutations occur in 10% of cases of X linked Alport syndrome. In 15% of the cases, 
the transmission is autosomal recessive, and is caused by mutations affecting COL4A3 or 
COL4A4 located on chromosome 2. The autosomal dominant form of Alport syndrome is 
very rare and is caused by heterozygous mutations in COL4A3 or COL4A4 genes. Affected 
individuals can also have sensironeural hearing loss and ocular abnormalities. Sensorineural 
hearing loss is the most common extrarenal manifestation and the progression of hearing 
loss often parallels the progression of renal disease. Anterior lenticonus, a conical protrusion 
of the lens in the anterior chamber, develops progressively and mainly occurs in male 
patients. The most common renal manifestation is hematuria.  
Prospective donors with a family history of Alport’s should be assessed by a urinalysis, 
estimation of glomerular filtration rate, a vision test and a hearing test. Male siblings aged 
>20 years without hematuria are very unlikely to have the disease and are suitable donors. 
Sisters of affected male recipients with X linked disease have a 50% risk of being carriers, 
unless the disease in the brother is caused by a neomutation. Gross et al reported the long 
term outcomes of six heterozygous mothers with microhematuria who had donated a 
kidney to their affected children. Three of the women developed new onset hypertension 
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and two developed proteinuria over a mean follow up time of 6.7 years. Renal function 
declined significantly in four of the donors [40]. A female relative without hematuria, has a 
low risk for being a carrier and is a suitable donor. Female relatives with proteinuria should 
be excluded from donation. Female relatives with persistent microhematuria are most likely 
carriers. Up to 25% of female carriers of X-linked Alport mutations develop renal failure and 
they should not donate [41]. Genetic analysis of COL4A5 genotype is not useful for 
determining the suitability of women for kidney donation given the absence of correlation 
between the genotype and the phenotype in women [35].  
Thin Basement Membrane Disease 
Thin basement membrane disease (TBMD) affects around 1% of the general population. 
Approximately 50% of patients have a heterozygous mutation in COL4A3 or COL4A4 
genes. Although the long term prognosis of the majority of patients with thin basement 
membrane nephropathy is excellent, some patients develop proteinuria and progressive 
renal failure, especially those with documented heterozygous mutations in COL4A3 or 
COL4A4 genes [35]. The clinical course of TBMD is generally benign. However, the duration 
of most longitudinal studies has been too short to reflect prognosis. One study reported that 
7% of patients with biopsy-proven TBMD had renal dysfunction with a serum creatinine 
level greater than 1.2mg/dl. Risk factors for progression are proteinuria, hypertension and 
abnormal renal function [42]. Other coexistent glomerular lesions, found in about 5% of 
patients with TBMN, namely IgA nephropathy, amongst others, can explain the abnormal 
renal function in these patients [43].  
Donation from patients with TBMD remains controversial, given the lack of long term 
studies that address the outcomes of kidney donation in these patients. Patients with 
hypertension, proteinuria, or abnormal kidney function should not donate. Careful 
assessment of the potential donor’s family history and extrarenal manifestations of Alport 
syndrome should be done. Patients with isolated glomerular hematuria must be assessed 
thoroughly for atypical features and, when these are present, a renal biopsy is advised to 
detect possible Alport syndrome and any other disease such as IgA glomerulonephritis. A 
kidney biopsy, however, might not distinguish between TBMD and early Alport’s 
syndrome [44]. Atypical features include episodic gross hematuria that is uncommon in 
TBMD, but common in IgA nephropathy and Alport’s. A family history of renal failure is 
common in IgA nephropathy and Alport’s but not in TBMD [45]. Prospective donors should 
be counseled that, although TBMD has a benign course in general, renal failure may occur 
and long term risks remain unknown.  
Systemic lupus erythematosus (SLE) 
SLE occurs in about 12% of first degree relatives of patients with SLE. Prospective donors 
should be screened for ANA (antinuclear antibody), complement levels and abnormal 
urinary findings. Antiphosholipd antibody testing is suggested if the medical history is 
positive for deep vein thrombosis, stroke, pulmonary embolism, fetal loss, 
thrombocytopenia, hemolytic anemia, or livedo reticularis. Family member of a patient with 
SLE who has a positive ANA has a 40 fold increased risk of SLE and should not donate [45].  
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3.2. Evaluation of renal function 
3.2.1. Glomerular Filtration Rate (GFR) 
The most common approach to estimating GFR is with a 24-hour urine for creatinine 
clearance. This is the method used by approximately 90% of transplant centers in US, with 
the remaining programs using a radioactive isotope or iodinated tracer [16]. Creatinine 
based estimation equations are not reliable in the donor population, who have normal 
kidney function and should not be used. However, inadequate collection, low protein diet, 
low muscle mass and other factors may lead to low creatinine clearances in those with 
actually normal kidney function. Radionuclide methods, including iodine 124-iothalamate 
or technetium 99m-diethylenetriamine are used if the 24-hour creatinine clearance is 
borderline. The general cutoff for most centers is GFR of 80 mL/min/1.73 m2, although as 
many as 20% of U.S. transplant centers would accept a creatinine clearance as low as 60 
ml/min/1.73m2 [12]. Some centers take into account the normal decline in GFR with aging at 
a rate of 4-5ml/min/1.73m2 per decade of life starting the age of 20, allowing for kidney 
donation at lower limits of GFR.  
3.2.2. Proteinuria 
Proteinuria should be assessed with a 24-hour urine collection. Spot urine protein to 
creatinine ratio may underestimate the level of proteinuria. Most programs use protein>300 
mg/day in a 24-hour urine collection as the cutoff to exclude donation [12,16]. Special 
attention should be made to transient causes of proteinuria, such as fever, urinary tract 
infections and exercise. When abnormal, the collection should be repeated to confirm the 
persistence of proteinuria.  
3.2.3. Hematuria 
Urinalysis is indicated in all prospective donors. Microscopic hematuria, defined as more 
than 3-5 RBC/HPF, needs further evaluation. Menstruation in premenopausal women 
should be ruled out as well as urinary tract infection. Persistent hematuria, confirmed on 
more than one urinalysis, deserves more investigation. Medical history should look 
carefully for a family history of TBMD, Alport’s, ADPKD. The concomitant presence of 
proteinuria or RBC casts or dysmorphic RBCs is suggestive of underlying glomerular 
disease. Patients with persistent isolated hematuria should have urine cytology and 
urological workup including cystoscopy. They should also be screened for nephrolithiasis 
by a CT urogram (routinely performed as part of CT angiogram; discussed next). African 
American patients should be screened for sickle cell disease. In the absence of any specific 
abnormalities, a kidney biopsy may be indicated looking for Alport’s, IgA nephropathy, 
among other pathologies [12,46]. If a full evaluation for persistent isolated hematuria is 
negative, most centers proceed with donation, since the risk for progressive renal disease is 
small. However, a survey of US transplant centers showed that 21% of programs 
automatically exclude potential donors with greater than 10 RBC/HPF, regardless of work-
up [16]. 
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3.2.4. Pyuria 
In the presence of pyuria, urinary tract infections and prostatitis in men should be ruled 
out. If pyuria is persistent, renal tuberculosis should be ruled out with 3 morning  
urine acid-fast bacilli cultures. If these tests are negative, a renal biopsy should be 
considered to rule out interstitial nephritis or chronic pyelonephritis. Donation is 
contraindicated if there is evidence of renal tuberculosis, or interstitial nephritis or 
pyelonephritis [45].  
3.3. Radiologic Evaluation of potential allografts 
CT-based imaging is routinely used to evaluate the potential donor’s anatomy. The 64 slice 
multidetector CT (MDCT) urogram and angiogram has become the gold standard imaging 
technique and has replaced the traditional arteriography and intravenous urography. 
MDCT can provide assessment of the renal vein and artery, ureteral structure, renal 
parenchymal lesions, renal cystic diseases, stones, and surrounding anatomic variant. In 
addition, MDCT can measure kidney volume, a more sensitive index of size than length as 
available from sonography [47].  
The left kidney is preferred for laparoscopic living donor nephrectomy because of its 
relative technical ease of removal and flexibility afforded by the longer left venous pedicle. 
MDCT permits detection of vascular abnormalities and variants. A right donor nephrectomy 
may be performed if complex vascular anatomy (e.g., multiple arteries or veins) is present in 
the left kidney. Preoperative imaging also helps identify the lower quality kidney (i.e., with 
incidental findings such as a small stone or hemorrhagic cyst), which is usually chosen in 
living donor transplantation [48].  
MDCT detects asymmetry in the size of the kidneys, in which case a renal scan (MAG3) may 
be needed and the lower functioning kidney would be chosen for donation. The urogram 
phase of MDCT can delineate the presence of stones and abnormalities in the collecting 
system, such as ureteral diverticulum, calyceal diverticulum, hydronephrosis and 
ureteropelvic junction obstruction, ureteral duplication that may alter the surgical approach. 
Up to 30% of kidneys evaluated by MDCT have incidental renal finding such as renal cysts 
or calyceal calcifications. Patients with multiple stones, large single stone (>1.5cm), 
nephrocalcinosis or medullary sponge kidney are excluded from donation. [26,45] MDCT 
can also detect the amount of perirenal fat. This information is useful to determine if donors 
with higher BMI are amenable to a laparascopic nephrectomy [26].  
Donation is usually contraindicated if the following are present [45]: 
 parenchymal abnormalities, including significant unilateral atrophy, or horseshoe 
kidney, presence of 2 or 3 cysts in each kidneys or complex or septated cyts, or 
angiomyolipoma 
 vascular abnormalities: significant atherosclerotic disease, fibromuscular dysplasia 
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Compared to MRI/MRA, MDCT has greater accuracy, is faster, and more cost effective. 
MRA has inferior resolution in evaluating the renal vein anatomy. It is useful in patients 
with iodinated contrast allergy [49].  
3.4. Surgical evaluation 
3.4.1. Workup and evaluation 
Potential donors should have a careful assessment of their perioperative risk for 
cardiovascular and pulmonary complications as well as thrombotic complications. 
Unstable coronary syndromes, decompensated heart failure, significant arrhythmias and 
severe valvular disease are contraindications to live kidney donation. Most of the 
intermediate predictors (mild angina, previous myocardial infarction, compensated or prior 
heart failure, diabetes mellitus) are also contraindications to donation. Other, minor 
predictors warrant further testing [12]. Cardiovascular testing includes a transthoracic 
echocardiography if the history is positive for chest pain, palpitations, dizziness, syncope or 
SOB and/or the physical exam reveal a murmur.  
A holter monitoring is indicated if history of arrhythmia, syncope, dizziness, or 
palpitations. Some transplant centers perform cardiac stress testing in prospective donors 
if they have one or more risk factors for coronary artery disease (age> 45 years old in men, 
and more than 55 in women, family history of premature coronary artery disease, 
hypertension, smoking).[26,45] However, the American College of Cardiology and the 
American Heart Association (ACC/AHA) guidelines published in 2007, recommended 
stress testing only in high risk patients with poor functional capacity, who are scheduled 
for vascular surgery and only when such testing would change the management [50]. In 
most instances, when evaluating prospective donors, cardiac stress testing does not 
appear to be indicated.  
Pulmonary function testing (PFT) 
Pulmonary function testing (PFT) is not routinely indicated unless the history and physical 
examination suggest lung disease, in which case further testing, including PFT is indicated. 
Moderate to severe pulmonary disease is a contraindication to living donation (Forced 
expiratory volume (FEV1) or forced vital capacity (FVC) less than 70% of predicted or FEV1: 
FVC ratio less than 65% on PFTs). Patients with asthma who are well controlled, and with a 
peak flow measurement less than 80% predicted, can be considered on an individual basis 
for live kidney donation [51].  
Smoking cessation 
Smokers have a higher risk of pulmonary and wound infections after surgery than 
nonsmokers. Observational evidence suggests a benefit to smoking cessation before surgery 
[52]. Abstinence of smoking for only 12 hours can greatly reduce carboxyhemoglobin 
concentrations, improve oxygen content and reverse negative inotropic and arrhythmic 
effects. Polycythemia and increased blood viscosity take a few days to reverse. Sputum 
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production declines 6 weeks after smoking cessation. Amsterdam forum guidelines 
recommend smoking cessation at least 4 weeks prior to donation.  
Alcohol abstinence 
An increase in postoperative morbidity is reported for alcohol abusers who drink at least 
five drinks (more than 60 g ethanol) a day. Observational evidence in other clinical suggest 
that alcohol withdrawal is recommended for at least 1 month before surgery [53]. 
Hypercoagulability 
Persons with personal history of one or more venous thrombosis or recurrent miscarriage or 
with a family history of thrombotic disease should be screened for hypercoagulable 
disorders. These include activated protein C resistance associated with factor V Leiden 
mutation, lupus anticoagulant, anticardioplin antibody, prothrombin gene mutation (FII-
20210), hyperhomocystenemia. Factor V-Leiden is the most common hereditary blood 
coagulation disorder, present in 3–8% of the healthy white population [54]. The odds ratio of 
a venous thrombolic event is 11 times greater in women taking oral contraceptives who 
have the Factor V Leiden mutation than for those who do not [55]. Some experts suggest 
that oral contraceptives and hormone replacement therapy should be withheld for 3 months 
prior to an elective surgery, given the high incidence of factor V Leiden in the population. A 
history of thrombotic disorders and presence of risk factors for future events (such as lupus 
anticoagulant, anticardiolipin antibody, abnormal activated protein C resistance ratio) as 
well as disorders requiring chronic anticoagulation are contraindications for kidney 
donation. However, a person with heterozygous factor V leiden mutation and without 
previous thrombotic episodes is not necessarily excluded from donation [12,26,45].  
3.5. Psychosocial evaluation 
Every prospective donor should undergo a psychosocial evaluation. This evaluation is 
especially important for unrelated donation. The psychiatric evaluation should be 
performed by a psychiatrist or mental health professional who has no personal and clinical 
relationship with the recipient. The evaluation should address the protection of donor’s 
confidentiality and should be performed in the absence of the recipient or recipient’s 
advocates. If translation is needed, translators should be unknown to recipient and donor.  
The evaluation would start by obtaining standard background information, such as donor’s 
educational level, living situation, religious beliefs, cultural background, and employment 
history. 
 The main elements of the psychosocial evaluation include the following: 
 The donor’s ability to make a decision should be assessed carefully, by evaluating for 
any underlying psychiatric disorders and any history of substance abuse. The donor 
should demonstrate a full capacity to give informed consent. 
 The evaluation should assess the donor’s accurate knowledge of recipient’s health 
benefits, and the accurate understanding of the donation process, and its physical and 
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mental consequences, including short term surgical complications and long term effects 
of donation on health outcomes. 
 The evaluation process should explore the nature of the relationship of the donor with 
the recipient, if any, and whether the donation was imposed by some expectations or 
perceived obligations on the part of either the donor or the recipient.  
 The evaluation should assess the donor’s motivation and inform the donor about the 
available option of not donating and the other treatment options available for the 
recipient. The prospective donor’s rationale and reasoning for donating should be 
explored. The evaluation should exclude coercion, secondary gain (monetary or other 
personal gain, such as stabilizing self-image or dealing with a psychological conflict).  
 The interview should inquire about the employment status of the donor and the 
availability of family support resources during the operative recovery period. The 
donor should have adequate financial and social support.  
 The outcomes of transplantation should be explored, these include increased self-
esteem after a successful transplantation and resentment and depression after an 
unsuccessful transplantation. In case of altruistic donation, the donor may experience 
depression because s/he may not witness and enjoy the positive outcome of the 
donation [45,56,57]. 
The major psychosocial contraindications for live donation include [57]:  
 active psychiatric illness or substance use 
 the presence of major financial stressors that could either have a coercive effect on the 
donor’s decision to donate, or interfere with the need for medical care after donation 
 evidence that the prospective donor has experienced pressure or coercion from others 
to donate 
 a limited understanding or capacity to understand the donor’s or the recipient’s risks 
and benefits from kidney donation 
 ambivalence about proceeding with the donation 
3.5.1. Financial aspects 
The economic impact of donation should be discussed with the prospective donor. The 
medical expenses are usually covered by the recipient’s insurance, or, in certain 
circumstances, by the Transplant Centers Organ Acquisition Fund. The expenses include: 
 the donor evaluation 
 the actual donation surgery  
 the post operative care 
Other non medical expenses such as travel and lodging expenses are not covered by the 
recipient’s insurance. 
The act of donation should not preclude the donor from obtaining medical insurance or 
increase the cost of insurance [45]. In the USA, the organ donor leave act was created in 1999 
and entitles the donor for 30 days of paid leave (Organ Donor Leave Act of 1999). However, 
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it is recommended that the prospective donor obtain health and life insurance prior to 
donation. 
The donor should be financially stable and free of financial hardship. The evaluation should 
explore the ability of the donor to cover financial obligations for expected and unexpected 
donation-related expenses. The donor should be able to afford time away from work mainly 
for unplanned extended recovery time [56].  
Paid donation 
Despite the legal constraints, paid donation and commercialism are common in many parts 
of the world. In the USA, the Uniform Anatomical Gift Act was created in 1968 in order to 
establish an ethical system that regulated the availability of organs for transplantation. 
Further advances were made in 1984 by the National Organ Transplant Act, which 
established the nationwide computer registry operated by the United Network for Organ 
Sharing. The same act prohibits buying or selling of organs in the United States. Similar laws 
have been enacted in other countries around the world. The Declaration of Istanbul on 
Organ Trafficking and Transplant Tourism strictly condemns all forms of organ trade [58]. It 
should be mentioned that other experts argue that the donors should be allowed to have 
monetary compensation and that the donors are entitled to use their bodies as they see fit. 
To address this issue and the concern of the short supply of kidneys available for donation, 
a regulated system of living unrelated paid donor kidney transplantation was legally 
adopted in Iran in 1988 [59]. However, most of the donors are poor and uneducated and 
follow up studies have shown that their lives have not improved after compensation for 
donation. Several types of regulated models offering indirect incentives or compensation for 
organ donations, such as health insurance, life insurance, disability coverage, or social 
benefits, have been proposed to encourage organ donations in developed countries [60]. 
Paid donation carries significant risks of exploitation of the poor. It poses significant health 
risks both for the donor and the recipient, including infectious complications, as well as 
other surgical and medical complications that, in part, are due to poor donor screening and 
evaluation [61].  
4. Risks to donor 
4.1. Surgical complications 
Open nephrectomy is now largely replaced by laparoscopic surgical techniques that account 
for more than 50% of donor nephrectomy procedures in the USA [62]. Compared to open 
nephrectomy, laparoscopic procedure provides shorter hospital stays (2 to 4 days compared 
with 3 to 7 days), less incisional discomfort, minimal surgical scar and better cosmetic 
appearance and an earlier return to work (12 to 21 days compared with 30 to 60 days) [63].  
Traditionally, laparoscopic nephrectomy (LN) is performed through 3 to 5 small incisions 
and has become the standard of care in most academic centers. Newer techniques are 
available; these include single port technique that has been shown to improve cosmetic 
results and lead to faster recovery [64-66].  
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Other new techniques include robotic assisted laparoscopic nephrectomy that allows the 
surgeon to dissect more meticulously and prevent bleeding more easily, along with shorter 
hospital stays [67].  
Conversion to open nephrectomy occurs in approximately 2% of procedures [63]. The 
perioperative mortality reported for living kidney donors including both open and 
laparoscopic methods is 0.03% [13,62], although in a recent survey, all reported deaths were 
after laparoscopic nephrectomy [68].  
The risk of perioperative and postoperative complications from unilateral laparoscopic 
nephrectomy is 10-15% [69]. These include, but are not limited to, bleeding, infection, bowel 
injury, hernia, and postanaesthesia depression. 
Matas at al [68] surveyed 234 kidney transplant programs to determine living donor 
morbidity and mortality for open nephrectomy, hand-assisted LN, and non-hand-assisted 
LN between 1999 and 2001: 
 52% of nephrectomies were done by open procedure, 21 % by hand-assisted 
Laparoscopic nephrectomy, and 27% via non-hand-assisted LN 
 2 donors (0.02%) died from surgical complications, both after laparoscopic nephrectomy 
 Reoperation was necessary in 0.4% of the open cases, 1.0% of the hand-assisted LN 
cases, and 0.9% of the non-hand-assisted LN cases 
 Complications not requiring reoperation were reported in 0.3% -1% of the cases without 
statistical difference between the groups 
 Readmission rate was higher for LN (1.6%) vs. open (0.6%) donors, mainly secondary to 
gastrointestinal symptoms, (nausea, vomiting, ileus, constipation) 
With more experience, the reported complications of laparoscopic nephrectomy have 
decreased, after an initial steep learning curve. The morbidity of the laparoscopic procedure 
has decreased with more experience, and the mortality rate remains low.  
A 2008 meta-analysis evaluated 73 studies that included 3751 and 2843 patients who had 
undergone laparoscopic surgery and open nephrectomy, respectively. Compared with open 
nephrectomy, the laparoscopic surgery group had a significantly shorter hospital stay and a 
quicker recovery. Both groups had similar rates of delayed allograft function and allograft 
loss [70]. 
While operative time is longer in laparoscopic nephrectomy (3-4 hours versus 2-3 hours in 
open nephrectomy), both procedures have similar recipient outcomes, graft function, 
rejection rate and graft survival [70,71].  
4.2. Life expectancy 
The survival of donors appears to be similar to that of the controls in the general population 
[8]. A Swedish study analyzed survival of 430 living donors. After 20 years of follow-up, 
85% of donors were alive, whereas the expected survival rate was 66%. The better survival 
among donors is likely due to the selection process involved in donor work-up. Patients 
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with health issues are ruled out. Mortality pattern was similar to that in the general 
population, the most common causes of death being cardiovascular diseases and cancer [72]. 
4.3. Likelihood of renal disease in donor 
4.3.1. Renal function and proteinuria 
Unilateral nephrectomy is followed by a compensatory increase in the GFR in the remaining 
kidney to achieve about 70%-80% of prenephrectomy GFR within days to weeks after 
nephrectomy. Some proposed that the degree of compensation may be better in younger 
patients [73]. The detrimental effect of kidney hyperfiltration and hypertrophy are more 
pronounced when nephron number is reduced in infancy than when nephron number is 
reduced later in life [74]. This has been shown in many studies, including the study of 56 
world war II soldiers, who had a unilateral nephrectomy at an average age of 25 years old, 
and who were reassessed 45 years following nephrectomy and compared to veterans with 2 
kidneys. Mortality, prevalence of HTN and proteinuria were equal in both groups. 10 
subjects had autopsy examinations and glomerular sclerosis was not increased [75].  
Studies examining renal outcome in donors are heterogeneous and frequently lack a control 
group. However, long term follow up studies, more than 30 years after nephrectomy, did 
not show an accelerated decline of renal function. The decline in renal function seemed to 
parallel the age related decline of healthy individuals with 2 kidneys.  
A study of 3,698 kidney donors from 1963 through 2007 showed that mortality of kidney 
donors was comparable to the general population. From 2003 till 2007, kidney function of 255 
donors was assessed by iohexol clearance and urinary albumin to creatinine ratio. The 
mortality was comparable to the general population. 85.5% of the donors had an iohexol GFR 
>60 mL/min/1.73 m2. Hypertension was noted in 32% of the donors, albuminuria (defined as 
urine albumin/creat ratio above 0.02) in 12.7%, and none of the donors with albuminuria had 
an iohexol GFR lower than 45 ml per minute per 1.73 m2. Importantly, the prevalence of 
hypertension and albuminuria in kidney donors were similar to those in controls who were 
matched for age, sex, race or ethnic group, and body-mass index. There was no excess risk of 
ESRD in donors. Factors linked to a reduced GFR in donors are the same as those that have 
been observed in the general population, namely, age and obesity [8]. 
In this study, a longer time since donation, however, was independently associated with 
albuminuria. This may be attributable to single nephron hyperfiltration, secondary to 
reduced renal mass but does not seem to be associated with higher risk of renal dysfunction.  
In a review that summarizes 48 studies that included a total of 5000 donors on average, 
kidney donation resulted in small increases in urinary albumin, which increased with the 
time after donation (three studies totaling 59 controls and 129 donors; controls 83mg/day, 
donors 147mg/day, weighted mean difference 66mg/day, 95% confidence interval (CI) 24–
108) [76]. Whether the hyperfiltration injury that is reflected by the albuminuria leads to a 
progressive deterioration in kidney function has been the subject of many debates.  
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In this same review, after an average of 7 years after donation, the average 24 h urine 
protein was 154 mg/day and the average GFR was 86 ml/min. Ten years after nephrectomy, 
donors had a GFR that was 10 ml/ min lower compared to controls. In addition 
approximately 12% of donors developed a GFR less than 60 ml/min during follow-up. 
However, after the initial decrement in GFR from the nephrectomy, there was no evidence 
of an accelerated loss in GFR over that anticipated with normal aging [76]. 
4.3.2. Hypertension 
Although some studies show that the prevalence of HTN among donors is identical to that 
observed in the general population [77], other studies did reveal that the incidence of 
hypertension increases after kidney donation [78,79].  
However, in most of these studies, this increase in arterial pressure is statistically significant 
but clinically irrelevant and most of the donors do not reach values to be considered as 
hypertensive [80]. In a metanalysis done by Boudville et al [79] in 2006, the authors 
described an increase of 5 mmHg in the 5–10 years following the kidney donation.  
However, racial disparities should be taken into account as it has been suggested recently 
that non-Caucasian donors could have a higher risk of HTN. This has been shown in a 
retrospective analysis of the prevalence of Diabetes, HTN and CKD among 4650 donors 
compared to the prevalence patterns in the 2005-2006 National Health and Nutrition 
Examination Survey (NHANES) for the general population. Compared to white donors, AA 
and hispanic donors were found to have increased risk of HTN, diabetes and CKD. The 
absolute prevalence of diabetes among all donors did not exceed that in the general 
population, but the prevalence of hypertension exceeded NHANES estimates in some 
subgroups. End-stage renal disease was identified in less than 1% of donors but was more 
common among black donors than among white donors [81]. These findings emphasize the 
importance of increased attention to health outcomes among demographically different 
donors and the need for close medical follow up.  
4.4. The need for transplantation of previous living kidney donors 
The UNOS database has recorded since 1987 an incidence of about 0.04% of living donors who 
have been listed for kidney transplantation, similar to the 0.03% incidence in the general US 
population. In the follow up study by Ibrahim et al of 3698 donors, 11 donors developed 
ESRD, at a rate of 180 cases per million per year, compared to the rate of 268 per million 
persons per year in the white population in USA. Three of the 11 donors had the same cause of 
ESRD as their sibling recipients, suggesting unrecognized familial renal disease or risk factors.  
Upon review of the OPTN (Organ Procurement and Transplantation Network) database, as 
of February 2002, a total of 56 previous living donors have been identified as having been 
listed for deceased donor kidney transplant. The majority of these patients originally 
donated a kidney to a sibling (86%); five patients donated to a parent, and three patients 
donated to a child, highlighting again the possible role of unrecognized familial risk factors 
for kidney disease [82].  
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According to the UNOS/OPTN database between 1993 and 2005, African-Americans 
constitute 40% of the donors on the waiting list for transplant, although they represent only 
14% of the whole living kidney donor population, emphasizing the fact that AA might be at 
greater risk for ESRD after kidney donation [15].  
The Amsterdam forum proposed the current UNOS policy for live kidney donors that 
assigns an allocation priority for a deceased donor kidney if the previous live kidney donor 
subsequently become a candidate for a kidney transplant later in life. However, there was 
no consensus to develop such a policy internationally [12]. 
5. Non directed donation 
As of January 2009, biologically unrelated donors constituted about 40% of the living donors 
in the USA. Most of these donors were emotionally related and have an apparent, strong 
and deep relationship with the recipient (spouse, close friend, significant other, adopted 
sibling). Prospective donors with a much more casual relationship with the recipient 
(coworkers, members of faith community) or with little or no relationship to donors 
(solicited through internet, media…) are becoming increasingly common and about half of 
unrelated donors fall into this category. 
Non directed donors, also called altruistic donors, or ‘Good Samaritan Donors’ donate their 
kidney to a completely unknown recipient, whom the donor might never meet. They 
represent about 1.5% of all living donors in the USA as of January 2009. This practice is not 
allowed in some countries in Europe and South America because of the fear that the donor 
might be selling his/her kidney. 
Generally, the recipient is a patient on the deceased donor list, with a compatible blood group, 
the most waiting time and a negative crossmatching. The nondirected donors play an 
important role in kidney paired donation and living donor exchange programs. The 
evaluation process of nondirected donors has a strong emphasis on the psychosocial aspects of 
the donation, exploring any false perceptions or covert depression. Nondirected donors might 
be at a greater risk for depression or regret since they might not be able to enjoy the positive 
psychological gain that comes from seeing the recipient benefit from their altruism [26,57]. 
6. Paired kidney donation 
Patients with potential donors who are incompatible due to ABO differences or positive 
crossmatch can still reap the benefits of living donation through kidney paired donation 
(KPD). A simple “two-way” exchange, or swap, can be arranged between two incompatible 
pairs or a more complicated combination can be achieved using many pairs in many 
different hospitals. Such a large exchange is often initiated by a non-directed donor. This 
concept of KPD was first suggested by Felix Rapaport in 1986 and in 1991, the first kidney 
exchange was performed in South Korea. The next year, the first KPD transplants were 
performed in the USA in 2000. As of the third quarter of 2010, over 1000 KPD transplants 
have been performed in the USA [57,83]. 
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